Compare ARK Genomic Revolution ETF (ARKG) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Charles Schwab Corporation Common Stock — how do they compare? ARK Genomic Revolution ETF trades at $44.48, while Charles Schwab Corporation Common Stock trades at $109.25 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock pays a 1.19% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | SCHW | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $108.02 |
52-Week Low | $24.02 | $85.35 |
Market Cap | — | $186.25B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
Charles Schwab (SCHW) trades at $108.63, up 0.59% today, approaching its all-time high of $109.05. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. Revenue grew to $23.92B in 2025 with net income margin expanding to 38.79%. Recent news highlights institutional buying and positive analyst coverage, though an insider sale and ongoing litigation present minor concerns.
Outlook remains positive with analyst consensus target of $122.33 suggesting 12.6% upside. Strong earnings growth, improving cash flow trends, and market leadership position support further appreciation. Key risks include market sensitivity to interest rates, competitive pressures, and potential regulatory impacts from ongoing litigation. The stock offers growth potential but requires monitoring of macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
